Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD~* Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.~* Caregiver will participate and be able to attend clinic visits with patient.~Exclusion Criteria:~* Significant neurological disease other than AD, or a major psychiatric disorder~* Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)~* Woman of childbearing potential

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- Bapineuzumab 0.5 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).